Trial
NCT00796445
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Melanoma
Intervention
GSK 2132231A
Why stopped
The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-05